



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

THE U.S. FOOD AND DRUG ADMINISTRATION WILL USE GENEGO'S METACORE FOR "OMIC'S" RESEARCH AND REVIEWING OF GENOMICS DATA

St. Joseph, Michigan, October 10th, 2005 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that the U.S. Food and Drug Administration (FDA) have licensed MetaCore for “OMIC’s” research and reviewing of genomics data. GeneGo and the FDA will also integrate MetaCore with ArrayTrack and make it available for FDA researchers, <http://www.fda.gov/nctr/science/centers/toxicoinformatics/ArrayTrack/>

The MetaCore platform allows scientists to concurrently visualize, map and network multiple types of data including gene expression, SiRNAi, proteomic, metabolomic, SAGE and SNP data, both from pre-clinical discovery and clinical studies.

“High throughput (HT) experimentation is increasingly important for life science research, and HT data is now included in many new drug applications submissions. The analysis of such complex datasets requires novel systems biology tools, such as MetaCore,” said Dr Tatiana Nikolskaya, founder and CSO of GeneGo Inc. “One important issue in FDA submissions is compatibility and cross-referencing of multiple types of pre-clinical and clinical data, which are collected at different times by different research groups. MetaCore offers both a functional framework and analytical engine for this.”

“Working with the FDA is very important for GeneGo and we are very pleased to announce this relationship,” said Julie Bryant, Vice President of Business Development at GeneGo. “Since MetaCore is already being applied in drug discovery by our pharmaceutical customers for a couple of years now, it is logical that it will be also used on the regulatory side as well.”

GeneGo has assembled the world largest manually curated database of human biology and medicinal chemistry, which includes genes, proteins, natural ligands, metabolites, drugs and diseases from millions of literature findings.

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 2.5, assists pharmaceutical scientists

in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com.

MetaCore™, MetaBase™ and MetaDrug™ are trademarks of GeneGo, Inc.

About Array Track

ArrayTrack provides an integrated solution for managing, analyzing, and interpreting microarray gene expression data. Specifically, ArrayTrack is MIAME (Minimum Information About A Microarray Experiment) supportive for storing both microarray data and experiment parameters associated with a pharmaco- or toxico- genomics study. Many statistical and visualization tools are available with ArrayTrack. ArrayTrack also provides a rich collection of functional information about genes, proteins and pathways for biological interpretation. The primary emphasis of ArrayTrack is the direct linking of analysis results with functional information for facilitating the interaction between the choice of analysis methods and the biological relevance of analysis results. Using ArrayTrack, user can easily select a statistical method applied to a stored microarray data to determine a list of differentially expressed genes and the gene list can be directly linked to pathways and gene ontology for functional analysis.